In this week’s episode of The Spotlight Roundup, we check in with Fireside Project, the first-ever 24/7 psychedelic peer support line; the State of Oregon forms an advisory board to oversee the implementation of psilocybin use in specialized clinics; and The American Journal of Psychiatry publishes new guidance on how to safety and effectively use Ketamine and Esketamine.
As we continue to strive to be the leading source for news and unique perspective within the emerging sector of medicinal psychedelics, we are excited to debut the Spotlight Roundup! This video series, produced in collaboration with Elk’s Pride Pictures, provides a concise and informative roundup related to some of the most important news developments happening within this rapidly expanding industry. From the latest IPO’s, to new clinical trials, the Spotlight Roundup covers everything you need to know!
MindMed’s Patent STRATEGY & WHY Haven’t We Covered It YET? (MMED/ MNMD)
Patents and IP are important because it allows companies to protect their innovations and re-coup sunk costs into research and development by giving them a set period of time that only they can profit from any inventions they developed.
Given the importance of patents, some people have reached out and have asked why I haven’t talked about MindMed’ patents more.
For example, if you go to their Investors deck, you will see that MindMed, (MMED: NEO), (MNMD : NASDAQ), has 45+ different patent applications. We definitely haven’t done 45 videos on the matter. And that is because we actually don’t know what most of these patent applications are!
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#mindmed #mmed #mnmdstock
The momentum is snowballing, and 2021 will be even bigger and better for psychedelics. After a year like 2020, it’s hard to know what the next year will bring. But we’ve got a feeling it’s going to be quite the ride for psychedelics.
BIG news for Cybin Inc. (CYBN: NEO) (CLXPF: OTC) and Numinus Wellness (NUMI: NEO)
(LKYSF: OTC).
First and foremost, Numinus announced that the company acquired NCT, a Toronto-based, fully operational neurology center with 13 doctors, 8 allied health staff, nurse practitioners, and physician assistants. NCT and Numinus plan to establish the first center for excellence in psychedelic neurology.
Speaking of centers of excellence, Cybin entered into an agreement with a company called Greenbrook TMS to establish mental health centers of excellence in order to facilitate R & D of psychedelic compound-based therapeutics for patients suffering from depression.
Why is this big news? Watch till the end to find out!
In other news, we are glad to announce that The Psychedelic Investor has entered into a collaboration with Psychedelic Spotlight, one of the biggest news sources for psychedelic-related news.
Twice a month, I will be discussing some of the major industry news among other psychedelic industry experts in Psychedelic Spotlight’s segment titled: “Spotlight Roundup”.
Check out my first appearance on their podcast by clicking the link below!
https://www.youtube.com/watch?v=UKGFXnsOlr8
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Timestamps
0:00 -Intro
2:40 – Numinus Acquisition of Neurology Center of Toronto
9:55 -Cybin Enters Agreement with Greenbrook
Links:
NUMINUS WELLNESS TO ACQUIRE NEUROLOGY CENTRE OF TORONTO, PLANS TO CREATE CENTRE FOR PSYCHEDELIC NEUROLOGY:
https://thepsychedelicinvestor.com/2021/07/06/numinus-wellness-to-acquire-neurology-centre-of-toronto-plans-to-create-centre-for-psychedelic-neurology/
CYBIN (NEO: CYBN, OTC: CLXPF) ENTERS INTO COLLABORATION AGREEMENT WITH GREENBROOK TMS TO ESTABLISH MENTAL HEALTH CENTERS OF EXCELLENCE:
https://thepsychedelicinvestor.com/2021/07/08/cybin-enters-into-collaboration-agreement-with-greenbrook-tms-to-establish-mental-health-centers-of-excellence/
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Numinus #Cybin #NUMIStock
Bob Parsons is an American entrepreneur and a Marine Corps…
Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy
When it comes to treating mental health conditions with psychedelic therapy, one of the most promising compounds is DMT, the main ingredient in the brew ayahuasca. While DMT may have many potential advantages over other similar compounds such as psilocybin, for example, its short duration of effect, the hallucination can be very intense.
It is an open question whether the mental health benefits we see from psychedelic therapy are due to the experience one undergoes when having a hallucination, or whether it comes strictly from the drug’s effects on the brain. If it is the latter, then hypothetically speaking, we could create a version of DMT that does not cause a hallucination.
Enter Psilera Biosciences.
Psilera is a psychedelic medicines company working to create next-generation psychedelics for use in therapeutic settings. Specifically, they aim to create non-psychedelic versions of classical psychedelics such as psilocybin, LSD and DMT.
PSIL-002 is Psilera’s version of non-hallucinogenic DMT. They recently completed a pre-clinical trial in mice that showed that their version of DMT was safe and non-psychedelic. Now they have to show that their version of DMT can treat depression and addiction, starting with alcoholism.
If Psilera’s DMT can treat these mental health conditions equally as well as regular DMT, but without the intense hallucination, then PSIL-002 would probably be the better compound.
It is exciting to see Psilera’s scientists working on answering the following questions:
Can DMT treat depression?
Can psychedelics help with depression?
Can psychedelics help with Mental Health?
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Video editing: @themyaholy @Psy_holy
#DMT #DEPRESSION #PSYCHEDELICTHERAPY
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
